companiesCompany
Xynomic Pharmaceuticals
aka Xynomic Pharmaceuticals Holdings, Xynomic Pharma
Xynomic Pharmaceuticals is a Chinese-American biotech that licensed the histone deacetylase inhibitor abexinostat from Pharmacyclics and is testing it with pazopanib in kidney cancer and alone in lymphoma.
Overview
Xynomic Pharmaceuticals is an oncology company with operations in Zhongshan, Guangdong and the San Francisco Bay Area. Its lead asset is abexinostat, a pan-histone deacetylase inhibitor in-licensed from Pharmacyclics (now part of AbbVie), which it has taken into a phase 3 trial with pazopanib in renal cell carcinoma and into follicular lymphoma studies in China. It also holds rights to the pan-RAF inhibitor XP-102 and other clinical-stage assets.
Headquarters
Zhongshan, CN
Scorecard
All companies#348of 1181 companies, score 10
- phase 3 +3
- modalities +2
- registry trials +5
0 approved, 1 in phase 3, 0 earlier, 0 targets, 7 registry studies. Formula on the scorecards page.
Type
biotech
Website